title: Downgrading MELD improves the outcomes after liver transplantation in patients with acute-on-chronic hepatitis B liver failure.
abstract: BACKGROUND
  High score of model for end-stage liver diseases (MELD) before liver transplantation (LT) indicates poor prognosis. Artificial liver support system (ALSS) has been proved to effectively improve liver and kidney functions, and thus reduce the MELD score. We aim to evaluate whether downgrading MELD score could improve patient survival after LT.
  
  
  RESULTS
  One hundred and twenty-six LT candidates with acute-on-chronic hepatitis B liver failure and MELD score ≥30 were included in this prospective study. Of the 126 patients, 42 received emergency LT within 72 h (ELT group) and the other 84 were given ALSS as salvage treatment. Of the 84 patients, 33 were found to have reduced MELD score (<30) on the day of LT (DGM group), 51 underwent LT with persistent high MELD score (N-DGM group). The median waiting time for a donor was 10 for DGM group and 9.5 days for N-DGM group. In N-DGM group there is a significantly higher overall mortality (43.1%) than that in ELT group (16.7%) and DGM group (15.2%). N-DGM (vs. ECT and DGM) was the only independent risk factor of overall mortality (P = 0.003). Age >40 years and the interval from last ALSS to LT >48 h were independent negative influence factors of downgrading MELD.
  
  
  CONCLUSIONS
  Downgrading MELD for liver transplant candidates with MELD score ≥30 was effective in improving patient prognosis. An appropriate ALSS treatment within 48 h prior to LT is potentially beneficial.
authors.affiliation: Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Ling
authors.forename: Xiao
authors.initials: X
authors.lastname: Xu
authors.forename: Qiang
authors.initials: Q
authors.lastname: Wei
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Liu
authors.forename: Haijun
authors.initials: H
authors.lastname: Guo
authors.forename: Li
authors.initials: L
authors.lastname: Zhuang
authors.forename: Jiajia
authors.initials: J
authors.lastname: Chen
authors.forename: Qi
authors.initials: Q
authors.lastname: Xia
authors.forename: Haiyang
authors.initials: H
authors.lastname: Xie
authors.forename: Jian
authors.initials: J
authors.lastname: Wu
authors.forename: Shusen
authors.initials: S
authors.lastname: Zheng
authors.forename: Lanjuan
authors.initials: L
authors.lastname: Li
mesh_terms: D000210:Acute-Phase Reaction / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D000328:Adult; D018450:Disease Progression; D015536:Down-Regulation; D005260:Female; D019694:Hepatitis B, Chronic / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008107:Liver Diseases / Q000145:classification* / Q000175:diagnosis / Q000473:pathology; D016031:Liver Transplantation / Q000379:methods* / Q000401:mortality / Q000502:physiology; D019164:Liver, Artificial; D008297:Male; D008954:Models, Biological; D011379:Prognosis; D012107:Research Design; D016879:Salvage Therapy; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000295:instrumentation / Q000379:methods; D016896:Treatment Outcome; D014218:Triage / Q000379:methods